A Relevant Meeting Point for the Asian Pharmaceutical Industry

SYFPAC participated in COPHEX 2026, held from March 31 to April 3 at KINTEX in Goyang, South Korea. The presence at the exhibition, organized together with local partner Hahnson Impex Company, provided the opportunity to engage directly with pharmaceutical manufacturers and industry professionals across the region, confirming COPHEX as a key platform for understanding market dynamics and emerging technological needs.

The Korean BFS Market: Established and Expanding

More than 30 pharmaceutical companies in Korea are currently using Blow-Fill-Seal technology, confirming that it is a well-established solution within the market. BFS is predominantly used for manufacture of ophthalmic, narcotic and inhalation products, while other applications like for example high-value biologics and oncology drugs still tend to prefer glass containers. For other segments — including general injectables, small-volume doses, preservative-free formulations and high-volume production — the adoption of Blow Fill Seal is steadily increasing, driven by stricter aseptic processing requirements aligned with EU GMP Annex 1.

Meeting Asian Demand Trends in Limited Production Spaces

Many pharmaceutical companies in Korea are currently considering expanding their production capacity to address the growing internal demand for ophthalmic and inhalation products, which are key application areas for BFS technology, while also being export-oriented, supplying products to regions such as Southeast Asia, the Middle East and South America. These demand trends and export orientation are presented as a challenge to pharmaceutical companies who are unable to increase their manufacturing space and are looking for a higher production rate within their limited available space.

These insights from the local market were further enriched by the contribution of SYFPAC’s Korean partner, Mr. YJ Bahng, who provided a direct perspective on current industry dynamics, noting that: “The market is increasingly looking for solutions that allow capacity expansion within constrained environments.”

As a result, this makes compact and integrated systems particularly relevant in the current scenario, including solutions such as SYFPAC DUO.

A Clear Demand for Closed Systems and Integrated Manufacturing Models

Another key insight emerging from COPHEX 2026 is the clear demand for continuous and closed systems within the Korean pharmaceutical market.

These requirements reflect the need for higher levels of sterility assurance and process control, which are increasingly considered in the evaluation of new manufacturing technologies.

As the local pharmaceutical industry is progressively moving towards more integrated and efficient manufacturing approaches, Blow-Fill-Seal technology plays an increasingly important role, supported by evolving regulatory requirements, production efficiency needs and space constraints.

In this context, integrated technologies such as SYFPAC, designed for efficiency, flexibility and sterility assurance, are expected to play a growing role in the evolution of pharmaceutical manufacturing.

Strong Interest in SYFPAC DUO Technology

The exhibition recorded a high level of attendance, with visitors already familiar with this revolutionary technology ever since the CPHI Worldwide 2024, showing strong interest in understanding the concepts behind the SYFPAC DUO solution.

From a technological perspective, customers clearly recognized the advantages of the system, particularly in terms of process integration and efficiency.

At the same time, discussions highlighted that the evaluation process is strongly influenced by the availability of industrial references. Since operational case histories remain a key factor in supporting decision-making, the upcoming installations of SYFPAC DUO platforms in Europe and the MENA region are expected with great interest considering that, while economic considerations are part of the discussion, validation and reliability are perceived as the primary drivers.